LianBio (NASDAQ:LIAN) Trading Down 5.3%

LianBio (NASDAQ:LIAN)’s stock price dropped 5.3% during trading on Friday . The company traded as low as $0.29 and last traded at $0.29. Approximately 2,150 shares were traded during mid-day trading, a decline of 100% from the average daily volume of 1,037,083 shares. The stock had previously closed at $0.31.

Analyst Ratings Changes

LIAN has been the topic of a number of recent analyst reports. Jefferies Financial Group lowered shares of LianBio from a “buy” rating to a “hold” rating and reduced their price target for the company from $7.00 to $4.00 in a research report on Friday, December 22nd. Bank of America lowered shares of LianBio from a “buy” rating to an “underperform” rating and reduced their target price for the stock from $5.00 to $3.00 in a research report on Wednesday, January 3rd.

LianBio Price Performance

The firm has a market capitalization of $31.73 million, a P/E ratio of -0.36 and a beta of 0.23. The stock’s 50 day moving average is $2.86 and its two-hundred day moving average is $3.32.

LianBio Announces Dividend

The company also recently announced a — dividend, which was paid on Thursday, March 14th. Shareholders of record on Tuesday, February 27th were paid a $4.80 dividend. The ex-dividend date of this dividend was Friday, March 15th.

Institutional Investors Weigh In On LianBio

Several large investors have recently bought and sold shares of the company. Affinity Asset Advisors LLC increased its position in shares of LianBio by 462.2% during the fourth quarter. Affinity Asset Advisors LLC now owns 3,779,694 shares of the company’s stock worth $16,895,000 after acquiring an additional 3,107,337 shares in the last quarter. 22NW LP increased its position in shares of LianBio by 1,466.1% during the third quarter. 22NW LP now owns 2,211,678 shares of the company’s stock worth $3,295,000 after acquiring an additional 2,070,455 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of LianBio by 32.7% during the third quarter. Price T Rowe Associates Inc. MD now owns 2,822,857 shares of the company’s stock worth $5,618,000 after acquiring an additional 695,979 shares in the last quarter. Citigroup Inc. bought a new stake in shares of LianBio during the first quarter worth $1,980,000. Finally, Renaissance Technologies LLC increased its position in shares of LianBio by 417.2% during the third quarter. Renaissance Technologies LLC now owns 315,000 shares of the company’s stock worth $630,000 after acquiring an additional 254,100 shares in the last quarter. Institutional investors own 74.85% of the company’s stock.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.